Technicals — Flat at HK$133.70 this morning after yesterday's push to a record HK$138.70. The MA stack is fully bullish (20-day at HK$112.69) and the cleared HK$130 now flips to support; RSI at 69.9 is borderline, with volume confirmation pending this afternoon's session.
Fundamentals — The CXO duo keeps resonating — WuXi Bio (2269, held) printed another high the same day. The warming peptide/small-molecule order cycle and interim-report visibility remain the spine, and the RMB-1 H-share incentive still aligns management.
News — No fresh filings; the HK$136 average bank target has been caught by the price — the CXO sector is now testing the earnings-drive-targets-higher loop, with interims as the next catalyst.
With the breakout confirmed, trailing the stop is the entire management plan: no adds in the RSI-70 zone, HK$150 as the measured-move target, and a break of HK$122 would brand it a failed breakout — take the loss and go.
A warming CXO cycle with peptide (GLP-1 spillover) order torque and utilization-driven operating leverage; incentives align management.
- Geopolitical (Biosecure-style) risk resurfacing
- Order-cycle volatility
- Near-term pullback risk from overbought levels
- 07-14LongHK$127.6 → open → HK$133.7+4.78%
- 雪球 · Post-record comments split between profit screenshots and bubble calls — in breakouts, the screenshot crowd always exits before the top-callers; it's traditionOriginal ↗
- 华尔街共识 · 8 analysts average HK$135.96 — 1.7% above spot; the breakout has caught the targets, and the pressure to raise now sits with the analysts